We use cookies to understand how you use our site and to improve the overall user experience. This includes personalizing content and advertising. Read our
Privacy Policy
At Profacgen, our Permeability Assay Services deliver predictive assessment of cellular uptake, membrane crossing, and oral bioavailability potential for protein degraders, enabling early identification of permeability liabilities and guiding medicinal chemistry optimization.
Proteolysis targeting chimeras (PROTACs) are catalytic heterobifunctional molecules that selectively degrade target proteins by recruiting ubiquitin E3 ligases. Protein degraders enhance the ability to drug biologically relevant targets through ubiquitylation and proteasome-dependent degradation. In the early stage of protein degrader development, permeability assay is crucial for estimating the potential of candidate molecules. Profacgen offers multiple permeability platforms to evaluate absorption, distribution, and cellular uptake characteristics.
Overview
Permeability assessment is critical for protein degrader success because these molecules face unique physicochemical challenges that limit cellular access:
Large molecular weight: PROTACs typically exceed 700 Da, placing them outside traditional Lipinski rule-of-five space. Elevated molecular weight correlates with reduced passive diffusion, increased polar surface area, and poorer membrane permeability, necessitating deliberate permeability engineering
Cellular uptake challenges: Degraders must cross plasma membranes to engage intracellular targets and E3 ligases. Poor permeability creates a disconnect between biochemical potency and cellular activity, leading to false negatives in screening and suboptimal lead selection
Oral bioavailability considerations: Beyond cellular uptake, degraders must achieve sufficient intestinal absorption for oral dosing. Permeability data informs formulation strategy, prodrug design, and route-of-administration decisions early in development
Principle: Evaluation of passive, transcellular permeation across artificial lipid membranes over a broad pH range
Variants: PAMPA-GIT for gastrointestinal absorption prediction, PAMPA-BBB for blood-brain barrier permeability, and Skin-PAMPA for transdermal penetration assessment
Advantage: Easier, faster, and less expensive than cell-based assays; ideal for early-stage screening and large compound libraries
Madin-Darby canine kidney cell line for high-throughput transport screening.
Cell model: High-monolayer integrity and morphologic homogeneity enabling robust, reproducible results in 24- or 96-well formats
Transfection capability: Easy expression of specific human transporters for customized transport studies
Consideration: Endogenous canine P-glycoprotein (Pgp) may interfere with permeability studies; appropriate controls and human transporter transfection mitigate this limitation
Key Readouts
Profacgen quantifies the essential parameters that define permeability quality and predict in vivo performance:
Apparent permeability (Papp): The rate of compound transport across the membrane barrier, normalized to surface area and initial concentration. Papp values >10 × 10−6 cm/s indicate high permeability; values <1 × 10−6 cm/s indicate low permeability. This parameter directly correlates with human fractional absorption
Efflux ratio: The ratio of basolateral-to-apical permeability divided by apical-to-basolateral permeability. Values >2 suggest active efflux (typically P-glycoprotein-mediated), indicating potential for limited brain penetration, drug-drug interactions, and intestinal secretion
Transport characteristics: Identification of passive diffusion versus active transport mechanisms, pH-dependent permeability profiles, and transporter involvement through inhibition studies and transfected cell models
Applications
Our permeability assays support diverse protein degrader discovery and development applications:
PROTAC optimization: Identification of permeability liabilities in lead series, guiding linker modification, warhead replacement, and physicochemical property adjustment to improve cellular uptake while maintaining degradation potency
Oral drug development: Prediction of intestinal absorption and bioavailability to inform formulation strategy, prodrug design, and route-of-administration decisions before investment in in vivo pharmacokinetic studies
Candidate prioritization: Multi-parameter scoring integrating permeability, solubility, metabolic stability, and degradation potency to identify development candidates with the highest probability of in vivo success
Multiple Assay Types: PAMPA, Caco-2, and MDCK platforms spanning rapid screening to physiologically relevant absorption prediction, enabling tiered evaluation from discovery through development.
Several Technology Platforms: Complementary artificial membrane, human intestinal epithelial, and canine kidney models with transfection capability for customized transporter studies.
Highly Reliable and Reproducible Results: Standardized protocols, validated cell models, strict monolayer integrity controls (TEER, permeability markers), and cross-platform correlation ensure data confidence.
Quality One-Stop Protein Degrader Service: Seamless integration with binding, ternary complex, ubiquitination, and degradation assays within a single platform, eliminating handoff inefficiencies and enabling mechanistic correlation.
A PROTAC series demonstrated potent biochemical ternary complex formation but weak cellular degradation. The team suspected poor membrane permeability as the limiting factor and required rapid, cost-effective screening to identify permeable analogs.
Objective:
To employ PAMPA as a primary filter to rank 30 analogs by passive permeability and prioritize candidates for cellular validation.
Approach:
Profacgen performed PAMPA-GIT at pH 6.5 and 7.4 to simulate gastrointestinal conditions across the compound series. Analogs were ranked by Papp and correlated with calculated physicochemical properties (molecular weight, polar surface area, hydrogen bond donors). Top-performing analogs were advanced to Caco-2 for confirmation, and cellular degradation was assessed in parallel.
Outcome:
PAMPA identified a clear permeability cliff at polar surface area >140 Å2. Three analogs below this threshold showed 10-fold improved cellular DC50 compared to high-PSA counterparts. The structure-permeability relationship guided focused medicinal chemistry, yielding a lead with sub-micromolar cellular potency and acceptable PAMPA permeability.
Scenario 2: Caco-2 Efflux Assessment for Brain-Penetrant Degrader
Program Context:
A CNS-targeted degrader program required brain penetration for efficacy. The compound showed good passive permeability but required confirmation of minimal P-glycoprotein efflux to predict central nervous system exposure.
Objective:
To characterize bidirectional transport in Caco-2, confirm P-gp involvement, and evaluate analogs with modified physicochemical properties to reduce efflux liability.
Approach:
Profacgen performed bidirectional Caco-2 permeability with and without the P-gp inhibitor verapamil. The efflux ratio was calculated and P-gp contribution quantified. A panel of analogs with reduced hydrogen bond donor count and increased lipophilicity was synthesized and evaluated in parallel. PAMPA-BBB provided orthogonal prediction of blood-brain barrier permeability.
Outcome:
The parent compound exhibited an efflux ratio of 8.5, indicating strong P-gp-mediated efflux. Optimized analogs with reduced H-bond donors achieved efflux ratios <2 while maintaining degradation potency. PAMPA-BBB confirmed improved passive permeability, and the lead analog progressed to in vivo brain penetration studies with predicted CNS exposure sufficient for target engagement.
A: PAMPA is the optimal first-line screen for early-stage programs due to its speed, low cost, and minimal compound requirements. Caco-2 is recommended for lead candidates requiring regulatory-grade absorption prediction. MDCK suits high-throughput campaigns with transporter-specific questions. We typically recommend a tiered approach: PAMPA for screening, Caco-2 for validation.
Q: Can permeability predict cellular degradation potency?
A: Permeability is necessary but not sufficient for cellular activity. Poor permeability typically explains disconnects between biochemical and cellular potency. However, good permeability must be coupled with efficient ternary complex formation and ubiquitination. Our integrated platform correlates permeability with cellular degradation to identify true bottlenecks.
Q: What is the molecular weight limit for degradable PROTACs?
A: While PROTACs typically exceed 700 Da, successful examples span 600–1300 Da. Molecular weight correlates inversely with permeability, but this relationship is modulated by polar surface area, hydrogen bond donors, and lipophilicity. We evaluate each compound individually and identify optimization vectors beyond simple molecular weight reduction.
Q: How do you handle low-solubility compounds?
A: Low solubility confounds permeability measurement by limiting available concentration. We employ DMSO stock solutions, cosolvents, and surfactants within validated ranges. For highly insoluble compounds, we report solubility-limited permeability and recommend formulation or structural modification strategies.
Q: Can you predict brain penetration?
A: Yes. PAMPA-BBB provides rapid prediction of blood-brain barrier permeability. Caco-2 and MDCK with P-gp assessment identify efflux liabilities that limit brain exposure. We integrate these data with physicochemical property analysis to predict CNS penetration and guide CNS-targeted degrader design.
Q: What is the typical turnaround for permeability assessment?
A: PAMPA screening of 20–50 compounds requires 5–7 days. Caco-2 bidirectional transport with TEER validation requires 2–3 weeks. MDCK high-throughput screening requires 1–2 weeks. Full integrated campaigns combining multiple platforms typically deliver within 3–4 weeks.
Ding X, Hu X, Chen Y, et al. Differentiated Caco-2 cell models in food-intestine interaction study: Current applications and future trends. Trends in Food Science & Technology. 2021;107:455-465. doi:10.1016/j.tifs.2020.11.015
Huang Y, Chen Y, Lu S, Zhao C. Recent advance of in vitro models in natural phytochemicals absorption and metabolism. eFood. 2021;2(6):307-318. doi:10.53365/efood.k/146945
Freeman BB, Yang L, Rankovic Z. Practical approaches to evaluating and optimizing brain exposure in early drug discovery. European Journal of Medicinal Chemistry. 2019;182:111643. doi:10.1016/j.ejmech.2019.111643
Online Inquiry
Fill out this form and one of our experts will respond to you within one business day.
